{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Very Good Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Minimal Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"Response Rates evaluated using the International Uniform Response Criteria the International Myeloma Working Group (2003).\n\nCR-Negative immunofixation on the serum and urine and Disappearance of any soft tissue plasmacytomas and 5% plasma cells in bone marrow VGPR-Serum and urine M-component detectable by immunofixation but not on electrophoresis or 90 or greater reduction in serum M-component plus urine M-component \\<100 mg per 24 h PR-50% reduction of serum M-protein and reduction in 24-h urinary M-protein by 90% or to \\<200 mg per 24 h MR-≥ 25% but \\< 49% reduction of serum M protein and reduction in 24 hour urine M protein by 50 - 89%, which still exceeds 200 mg/24hrs. In addition; if present at baseline, 25-49% reduction in the size of soft tissue plasmacytomas also required No increase in size or number of lytic bone lesions.\n\nSD-Not meeting criteria for CR, VGPR, PR or progressive disease PD-Laboratory or Biochemical Relapse increase of 25% from baseline","groups":[{"description":"All patients received oral panobinostat, lenalidomide and dexamethasone as per protocol","id":"OG000","title":"Panobinostat, Lenalidomide and Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"up to 4 years","title":"Response Rates for Len Refractory Patients","type":"SECONDARY","unitOfMeasure":"Participants"}